SAGE-217 in major depressive disorder: A multicenter, randomized, double-blind, Phase 2 placebo-controlled trial

Authors
Category Primary study
JournalEUROPEAN NEUROPSYCHOPHARMACOLOGY
Year 2019
This article has no abstract
Epistemonikos ID: 3ea5edc8e2716434eff6be62b7b7b28d81909f08
First added on: Feb 10, 2025